Aeglea BioTherapeutics, Inc./$SYRE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aeglea BioTherapeutics, Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Ticker
$SYRE
Sector
Primary listing
Employees
87
Headquarters
Website
SYRE Metrics
BasicAdvanced
$1.8B
-
-$2.85
2.83
-
Price and volume
Market cap
$1.8B
Beta
2.83
52-week high
$24.03
52-week low
$10.91
Average daily volume
1.2M
Financial strength
Current ratio
6.487
Quick ratio
6.382
Profitability
Effective tax rate (TTM)
-0.00%
Management effectiveness
Return on assets (TTM)
-28.48%
Return on equity (TTM)
-49.83%
Valuation
Price to book
4.7
Price to tangible book (TTM)
4.7
Price to free cash flow (TTM)
-8.598
Free cash flow yield (TTM)
-11.63%
Free cash flow per share (TTM)
-2.718
Growth
Earnings per share change (TTM)
-183.33%
3-year earnings per share growth (CAGR)
-55.03%
10-year earnings per share growth (CAGR)
-39.94%
Bulls say / Bears say
Extended follow-up Phase 1 results for SPY001 presented at DDW 2025 showed a good safety profile in all dose groups, a half-life over three times longer than vedolizumab—supporting potential maintenance dosing every six months—and rapid, sustained α4β7 receptor saturation for more than six months. This allowed progression to a Phase 2 UC trial scheduled for mid-2025 (Nasdaq)
As of March 31, 2025, Spyre reported $565 million in cash, cash equivalents, and marketable securities, providing funding into the second half of 2028 to support multiple clinical milestones (Nasdaq)
Within nine months, Spyre launched four separate Phase 1 trials (SPY001, two SPY002 candidates, and SPY003) and now has fully funded Phase 2 trials planned that are expected to yield over seven proof-of-concept readouts in markets worth approximately $50 billion yearly, highlighting strong pipeline execution (Nasdaq)
The 2025 Q2 10-Q warns that if Spyre and the FDA or other regulators do not agree on the trial design or timelines for SKYWAY-RD and SKYLINE-UC, this could lead to higher costs or delays, which would have a material impact on the business (SEC)
The filing also states that success relies on achieving in humans the prolonged half-lives seen in non-human primates; if future trials fail to replicate these results, the clinical and commercial prospects would be seriously undermined (SEC)
In August 2025, Spyre’s Compensation Committee awarded inducement stock options for 60,400 shares to five non-executive employees under the 2018 Equity Inducement Plan, which could dilute current shareholders (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aeglea BioTherapeutics, Inc. stock?
Aeglea BioTherapeutics, Inc. (SYRE) has a market cap of $1.8B as of October 28, 2025.
What is the P/E ratio for Aeglea BioTherapeutics, Inc. stock?
The price to earnings (P/E) ratio for Aeglea BioTherapeutics, Inc. (SYRE) stock is 0 as of October 28, 2025.
Does Aeglea BioTherapeutics, Inc. stock pay dividends?
No, Aeglea BioTherapeutics, Inc. (SYRE) stock does not pay dividends to its shareholders as of October 28, 2025.
When is the next Aeglea BioTherapeutics, Inc. dividend payment date?
Aeglea BioTherapeutics, Inc. (SYRE) stock does not pay dividends to its shareholders.
What is the beta indicator for Aeglea BioTherapeutics, Inc.?
Aeglea BioTherapeutics, Inc. (SYRE) has a beta rating of 2.83. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.